Phase I Trial of GFR4 CART Cells in Adult Patients with Recurrent or Metastatic Medullary Thyroid Cancer
Enrolling By Invitation
18-99 years
All
Phase
1
18 participants needed
1 Location
Brief description of study
This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells expressing a single-chain scFv targeting GFRa4 with tandem TCR/CD3 and 4-1BB (TCR/4-1BB) costimulatory domains (referred to as CART-GFRa4) in patients with incurable medullary thyroid cancer (MTC).
This is a Phase 1 study evaluating the safety and feasibility of CART-GFRa4 cells following lymphodepletion with fludarabine and cyclophosphamide in a 3+3 dose escalation design.
Patients will be identified through the clinical practices of the investigator or sub-investigators and through referrals from outside hospitals and physicians.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Thyroid Cancer
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
09 Mar 2024.
Study ID: 848848
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
